Recent Advancements of Treatment for Leptomeningeal Carcinomatosis

Ho-Shin Gwak, M.D., Ph.D., 1 Sang Hyun Lee, M.D., Ph.D., 2 Weon Seo Park, M.D., Ph.D., 3 Sang Hoon Shin, M.D., Ph.D., 4 Heon Yoo, M.D., Ph.D., 4 Seung Hoon Lee, M.D., Ph.D., 4

Department of System Cancer Science, 1 Graduate School of Cancer Science and Policy, Departments of Diagnostic Radiology, 2 Pathology, 3 Neuro-Oncology Clinic, 4 National Cancer Center, Goyang, Korea

Treatment of Leptomeningeal carcinomatosis (LMC) from solid cancers has not advanced noticeably since the introduction of intra-cerebrospinal fluid (CSF) chemotherapy in the 1970's. The marginal survival benefit and difficulty of intrathecal chemotherapy injection has hindered its wide spread use. Even after the introduction of intraventricular chemotherapy with Ommaya reservoir, frequent development of CSF flow disturbance, manifested as increased intracranial pressure (ICP), made injected drug to be distributed unevenly and thus, the therapy became ineffective. Systemic chemotherapy for LMC has been limited as effective CSF concentration can hardly be achieved except high dose methotrexate (MTX) intravenous administration. However, the introduction of small molecular weight target inhibitors for primary cancer treatment has changed the old concept of ‘blood-brain barrier’ as the ultimate barrier to systemically administered drugs. Conventional oral administration achieves an effective concentration at the nanomolar level. Furthermore, many studies report that a combined treatment of target inhibitor and intra-CSF chemotherapy significantly prolongs patient survival. Ventriculolumbar perfusion (VLP) chemotherapy has sought to increase drug delivery to the subarachnoid CSF space even in patients with disturbed CSF flow. Recently authors performed phase 1 and 2 clinical trial of VLP chemotherapy with MTX, and 3/4th of patients with increased ICP got controlled ICP and the survival was prolonged. Further trials are required with newly available drugs for CSF chemotherapy. Additionally, new LMC biologic/pharmacodynamic markers for early diagnosis and monitoring of the treatment response are to be identified with the help of advanced molecular biology techniques.

Key Words: Cancer · Cerebrospinal fluid · Chemotherapy · Leptomeningeal carcinomatosis · Lumbar · Ventricle.

INTRODUCTION

Leptomeningeal carcinomatosis (LMC) is a dismal terminal stage disease of solid cancer that is devastating to the patient. Overall survival (OS) of patients with LMC is approximately 6–8 weeks, and intra-cerebrospinal fluid(CSF) chemotherapy show a survival benefit ranging from 3–9 months according to clinical variables. 15,16,46

Problems of intra-CSF chemotherapy include marginal survival benefit over systemic chemotherapy, difficulty of repeated drug injection, poor symptom improvement, and the occurrence of rare but serious side effects such as encephalopathy. 12,13,18 Among these, CSF flow disturbance, manifest as increased intracranial pressure (ICP) and/or hydrocephalus, is not only a poor prognostic factor but also one of the reasons for treatment failure as it prevents even distribution of injected drugs within the CSF space. 24,25,27 Research from the 1990s report that CSF flow disturbance is found in 40–60% of patients with LMC based on radionuclide cisternography. 20,21 Once-disrupted CSF flow hardly recovers and increases the risk of encephalopathy via transependymal drug concentration gradient. Most patients quit chemotherapy to selectively receive a ventriculo-peritoneal shunt. 16,18 Reported clinical studies are mainly retrospective, with a small number of patients, limited number of drug injection, and heterogeneous primary cancers. It is therefore difficult to draw any decisive conclusion about the effectiveness of intra-CSF chemotherapy. 25,26,30,31,35,45,66

Chemotherapy for LMC is not curative but palliative. However, studies reporting the response of LMC-related symptoms are rare and the criteria for improvement are subjective. 29,30,34 Some studies suggested that CSF profiles can be prognostic indicators, but show inconsistent findings of CSF profile change.
Thus, to achieve a therapeutic concentration (>1 μM) of MTX ance rate i.e., 3 μM, we have predicted CSF levels of methotrexate (MTX) with clear achievement of even distribution of drugs throughout the neuraxis. It is difficult to estimate the number of clinicians and the frequency at which they apply intra-CSF chemotherapy in patients with poor prognosis, systemic cancer burden, and poor performance profiles. Patients need surgery for subcutaneous intraventricular reservoir for stable drug injection, and require evaluation of physiologic CSF flow and monitoring of drug concentration to avoid toxicities. Despite these difficulties, more aggressive intra-CSF chemotherapy prolongs patient survival in studies of one primary cancer with multiple drug injection and/or salvage intra-CSF chemotherapy.

Recently, there are two new trials in the treatment of LMC from solid cancer. First is the increasing application of receptor tyrosine kinase inhibitor (RTKi) for primary cancers, such as epidermal growth factor receptor (EGFR) inhibitor and HER-2 monoclonal antibody in addition to conventional intra-CSF chemotherapy. Prolonged survival is clinically observed in patients who receive RTKi comitant with intra-CSF chemotherapy. The second is clinical trial of ventriculolumbar perfusion (VLP). VLP is expected to circumvent ineffective drug delivery in LMC patients with disturbed CSF flow but was halted due to technical complexities. Authors successfully finished VLP phase 1 with pharmacokinetic data and the following phase 2 trial proved the effectiveness of VLP in LMC patients with increased ICP and prolonged patient survival.

**RESULTS OF LMC TREATMENTS OVER THE DECADES**

**Treatment modalities for LMC**

Treatments for LMC should cover the whole-neuraxis as the disease spreads. In this context, even whole brain radiation therapy (WBRT) is not an appropriate therapeutic modality for LMC, as it does not cover the entire CSF space and besides, cancer cells move along with the CSF flow. Recent retrospective study on 125 non-small cell lung cancer (NSCLC) patients with LMC demonstrates a lack of effectiveness of WBRT on patient survival. Seven of these patients with intrathecal chemotherapy show significantly prolonged survival.

Meanwhile, either systemic or intrathecal chemotherapy achieves even distribution of drugs throughout the neuraxis. Pharmacokinetic studies with animal models done in the 1970’s have predicted CSF levels of methotrexate (MTX) with clearance rate i.e., 3-5% of systemically administered MTX penetrates the blood-brain barrier (BBB) at a half-clearance time of 6 hours. Thus, to achieve a therapeutic concentration (>1 μM) of MTX in the CSF, grams of MTX are required to be administered intra-venously for days. Single intraventricular injection of MTX (6.25 mg/m²) can achieve therapeutic concentration in the lumbar space for 48 hours at a minimal systemic absorption (<0.1 μM). Additionally, use of intraventricular Ommaya reservoir has the advantage of patient comfort especially in repeated frequent injection, prevention of drug leakage, and better drug distribution as compared to the intrathecal (via lumbar puncture) chemotherapy. Thus, studies with repeated aggressive intra-CSF chemotherapy mostly adopt the Ommaya reservoir for intraventricular chemotherapy.

Two prospective studies on the survival of breast cancer patients with LMC compare systemic chemotherapy and radiation therapy with additional intra-CSF chemotherapy. Both studies report that intra-CSF chemotherapy does not prolong patient survival and significantly increases associated neurotoxicities. However, in both studies, systemic chemotherapy is not clearly defined, but described as ‘appropriate chemotherapy’. Furthermore, ill-defined delayed neurotoxicity was unable to be differentiated from disease progression.

**Clinical studies reporting results of intra-CSF chemotherapy**

Although well-controlled, prospective or randomized study to evaluate the benefit of intra-CSF chemotherapy are lacking, intra-CSF can evidently prolong OS of patients with LMC, as compared to the untreated (Table 1). However, such studies are limited by factors such as the small number of patients, heterogeneous primary cancer, different systemic cancer burdens, and various rounds of intra-CSF chemotherapy. Findings of previous studies show that 1) primary cancer of breast has a favorable prognosis as compared to lung cancer and/or melanoma, 2) more aggressive intra-CSF chemotherapy regimen/schedules show prolonged survival as a benefit of repeated treatment, and 3) increased intracranial pressure indicating a disrupted physiologic CSF flow is not only a bad prognostic factor but also a major obstacle to intra-CSF chemotherapy. Chamberlain and Kormanik report clinical results of 32 LMC patients from NSCLC after a relatively intense schedule of intraventricular chemotherapy, in which median survival is prolonged to 5 months. The ‘intense schedule’ includes the ‘concentration×time’ schedule administration of MTX (2 mg for 5 consecutive days every other week for 8 weeks), the second (cytosine arabinoside) and the third (Thiotepa) salvage intraventricular chemotherapy. In our study on the institutional data, median survival of 105 patients with LMC from NSCLC, who underwent a median 5 rounds of intraventricular chemotherapy via Ommaya reservoir, is 3.0 months. Although the median OS is not impressive, we show the efficacy of intraventricular chemotherapy for patient survival using ‘time-dependent covariate analysis’ to eliminate the possibility of higher frequency chemotherapy given to patients who lived longer (the reverse-causation problem).

Due to the rarity of available drugs for intra-CSF chemotherapy, MTX in combination with or salvaged by cytosome arabinos-
side (Ara-C) with hydrocortisone or Thiotepa comprises most treatment regimens (Table 1). Although some patients with contraindications or resistance to MTX have some benefit from Ara-C or Thiotepa, it is still unclear whether MTX in combination with other drugs is superior to MTX monotherapy as the 1st line therapy. One randomized controlled study compares DepoCyt (sustained-release formulation of cytarabine; 50 mg every 2 weeks) to conventional intra-CSF MTX (10 mg twice a week for 4 weeks) in patients with LMC from solid tumors. Apparent prolonged OS in DepoCyt-treated patients (105 days vs. 78 days) has no statistical significance, but time-to-neurological progression is significantly delayed (58 days vs. 30 days)

**REMAINED PROBLEMS IN THE INTRAVENTRICULAR CHEMOTHERAPY FOR LMC**

**Diagnosis and Treatment response measurements**

LMC is defined as malignant cells in the CSF on cytology examination. However, pathologic process usually occurs in the subpial CSF space, where cancer cells get lodged and cause neuropsychological dysfunction and CSF flow obstruction. Hence, the low probability of floating cancer cells within a small amount of CSF results in 50–60% sensitivity of single CSF cytology despite overt LMC-related symptoms. Nevertheless, we obtain a sensitivity of 85–90% on repeated cytology examinations. T1-weighted gadolinium enhancement MRI (Gd-MRI) of both brain and spine is the standard diagnostic procedure for patients with LMC to support the diagnosis and assess the extent of disease, including bulky disease. Although the ‘evident enhancement of leptomeninges’ on Gd-MRI reveal a sensitivity around 70% for diagnosis of LMC, the sensitivity may be as high as 90%. This is because it frequently contains ‘suggestive findings’ of enhancement of dura, ventricular ependyma with or without ventriculomegaly or nodular enhancement in subarachnoid space in patients with overt LMC-related symptoms. Combined with clinical features of LMC, Gd-MRI can support a diagnosis of LMC in patients with negative CSF cytology. Thus, in patients with known primary cancer who show suspected symptoms of LMC, Gd-MRI should be done before painful lumbar puncture, as it mimics leptomeningeal enhancement along with the infectious condition of CSF.

In the context of the false negative CSF cytology for diagnosis, one-time negative conversion of CSF cytology after intra-CSF chemotherapy does not constitute a treatment response. Chamberlain and Kormanik propose complete response of CSF cytology as ‘two consecutive negative results at least one week apart and sustained for at least one month’ and partial response as ‘from positive to suspicious’ under the same conditions. However, these CSF responses are neither correlated with patients OS nor sustained for several months in patients with LMC from solid cancers, in contrast to prolonged CSF negative conversion in patients with leukemia at chemo-off period.

**Table 1. Clinical results of intra-CSF chemotherapy in the literatures**

| Author (year)                    | Primary cancer (tumor type) | Treatment (No. of patients) | Median survival | Response |
|---------------------------------|-----------------------------|----------------------------|-----------------|----------|
| Wasserman et al. (2002)         | Breast >> lung > melanoma   | Intraventricular MTX* (n=30) | 5.8 months      | 50% (clinical) 23% (cytological) |
| Ongroo et al. (1982)            | Breast                      | Intraventricular MTX* (n=25/33) | 6 months intra-ventricular MTX (n=16) | 80% (clinical) 81% (cytological) |
| Hitchins et al. (1987)          | SCLE, breast >> others      | Intraventricular MTX* (n=44) | 2 months intrathecal MTX (n=9) | 80% (clinical) 81% (cytological) |
| Fizazi et al. (1996)            | Breast                      | Intrathecal MTX* (n=62)     | 8 weeks         | 55% (clinical) 50% (cytological) |
| Chamberlain and Kormanik (1998) | NSCLC                       | Intraventricular MTX* (n=32) | 7 weeks low-dose MTX (n=21) | 32% (clinical) 24% (cytological) |
| Waki et al. (2009)              | Lung, breast >> others      | Intrathecal MTX* (n=31/85)  | 14 weeks high-dose MTX (n=41) | 32% (clinical) 53% (cytological) |
| Gauthier et al. (2010)          | Breast                      | Intraventricular MTX* (n=80/91) | 144 days intrathecal-treated | 55% (mixed clinical & cytological criteria) |
| Gwak et al. (2013)              | NSCLC                       | Intraventricular MTX* (n=105) | 3.0 months      | 29% (ICP) 13% (cytological) |

*Some patients received in combination or salvage treatment with Cytosine arabinoside and/or Thiotepa, †Number of treated patients/all patients. CSF : cerebrospinal fluid, MTX : methotrexate, ICP : intracranial pressure, SCLE : small cell lung ca., NSCLC : non-small cell lung ca.
pharmacokinetics and chronic dosing study in the non-human primate before clinical trials.

**RECENTLY INTRODUCED CYTOTOXIC DRUGS FOR INTRA-CSF CHEMOTHERAPY**

List and clinical results are summarized in Table 2.

**Topotecan**

Topotecan, a topoisomerase I inhibitor shows a wide-spectrum of anti-tumor activity. While it has a relatively high CSF penetration rate (30%), systemic or central nervous system (CNS) toxicity is rarely observed. These properties suggest the intrathecal use of topotecan, and non-human primate pharmacokinetic study show a 450-fold higher CSF concentration after an intraventricular dose of 0.1 mg than systemic administration. Subsequently, phase I trial was performed in patients with LMC from various cancers including leukemia, breast cancer, lung cancer and gliomas. At a maximal tolerable dose (MTD) of 0.4 mg, lumbar CSF concentration at 2 hours is 1 uM at an average 15% of ventricular concentration. Among the 23 patients observed, grade 3 transient arachnoiditis occurred in 3 patients and 1 patients showed grade 3 ataxia, which did not completely recover. All 3 leukemia patients and 3 of the 13 glioma patients showed CSF cytology responses but following phase II study is not yet performed.

**Mafosfamide**

Mafosfamide is a reactivated formulation of cyclophosphamide, which shows wide spectrum anti-tumor activity but typically needs hepatic enzyme activation to become cytotoxic. As cyclophosphamide is effective for CNS embryonal tumors, which have a predilection for LMC, clinical trials are performed on young children with these tumors to prevent LMC and to delay or possibly avoid whole neuraxis radiation. Initial phase I study failed to achieve cytotoxic CSF concentration (>10 uM) due to dose-limiting toxicity (DLT) of headache and/or irritability and rapid clearance at 5 mg of mafosfamide. However, in the following phase I study, patients could tolerate 14 mg of mafosfamide with premedication of steroid and morphine and had effective mafosfamide CSF concentration. The recently published result of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial CNS tumor: a pediatric brain tumor consortium study suggests that the incorporation of intrathecal mafosfamide to systemic chemotherapy is feasible.

**Gemcitabine**

Gemcitabine, a deoxy-citidine analog anti-metabolite, shows anti-tumor activity against various solid tumors. As gemcitabine is water-soluble but barely penetrates blood-CSF barrier after intravenous administration, it is considered as an excellent candidate for intrathecal chemotherapy. Non-human primate study of intraventricular gemcitabine administration is promising as it reveals negligible plasma gemcitabine concentration with effective CSF concentration based on pharmacokinetics. On 5 mg per week for 4 weeks schedule, there is no discernible neurotoxicity except transient CSF pleocytosis. Thus, a phase 1 clinical trial has been launched with a basal dose of 5 mg per week (1/10th of the non-human primate dose equivalent based on the different CSF volume). However, DLT of 2 severe neurotoxicities (transverse myelitis and somnolence) occurred at the 10th and 7th administration of intrathecal gemcitabine without objective response other than stable disease. Phase I trial is prematurely discontinued due to different cytidine deaminase (converting gemcitabine to its inactive form) levels between non-human primates and human, lack of chronic dosing study, and prior treatment of intrathecal chemotherapy and radiation in patients show DLTs.

**Busulfan**

Non water-solubility of busulfan precludes its intrathecal administration while it shows activity against cyclophosphamide resistant neoplasms. Microcrystalline formulation (Starject busulfan, SuperGen Inc., San Ramon, CA, USA) solves the solu-
bility problem, and successful intrathecal Starject busulfan in a nude rat model has prompted phase 1 clinical trial in children with primary brain tumors (PBT-C-004)\(^{30}\). Effective CSF concentration of 50–150 ug/mL is achieved with transient grade 3 toxicities of vomiting, headache and arachnoiditis on a 5–17 mg twice weekly for 2 weeks schedule; 13 mg of busulfan is recommended for future phase II study.

**ACNU (3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride)**

Levin et al.\(^{40}\) tested chloroethy nitrosoureas, which have advantage of non-cell cycle specific agents, in a beagle model. Among the nitrosoureas, water-soluble ACNU is best tolerated, and based on the observed clearance rate, the phase I baseline dose of 8 mg/week every other week is suggested\(^{41}\). Accumulated dose of up to 104 mg (8 mg per week×13 times) leads to no bone marrow suppression in patients. Neurotoxicities of headache, nausea, vomiting, and radiculopathy are all transient.

**MONOCLONAL ANTIBODIES AND TARGET INHIBITORS FOR INTRA-CSF CHEMOTHERAPY**

Monoclonal antibodies

As monoclonal antibodies do not cross the BBB due to molecular weight, successful intrathecal Rituximab treatment in lymphoma and leukemia has prompted the introduction of monoclonal antibodies to intra-CSF chemotherapy. Among these, Herceptin (transtuzumab) is the most widely used monoclonal antibody targeting LMC from HER-2 positive breast cancer. Despite the absence of systematic phase I trial, single dose is escalated up to 150 mg but the interval is variable according to case reports\(^{42}\). A pooled analysis of intrathecal Herceptin reveals 2/3rd CSF response, median OS of 13.5 months and median PFS of 7.5 moths\(^{43}\). Other monoclonal antibodies, combined with immunotoxin or radio-isotope to increase cancer cell specificity or lethal effect are tried in animal models but not in human yet.

Receptor tyrosine kinase inhibitors

Recent studies report that patients with LMC from NSCLC, who receive intrathecal or intraventricular chemotherapy with concurrent RTKi, have prolonged survival compared to patients with intra-CSF chemotherapy alone\(^{14,25,47}\). RTKi’s partially cross the BBB and oral dose regimen of erlotinib and gefitinib achieve effective CSF concentration in this low bound-protein compartment\(^{31,48}\). Frequent clinical response in patients with parenchymal brain metastasis and/or LMC from NSCLC after RTKi, is an impetus to evaluate its efficacy in further clinical trials according to EGFR mutation.

**VENTRICULO-LUMBAR PERFUSION TO OVERCOME CSF FLOW DISTURBANCE**

CSF flow obstruction, found in >50% LMC patients, is a long standing major obstacle to intraventricular chemotherapy as it hinders effective distribution of injected drugs\(^{16}\). Most studies measuring ICP in LMC patients agree that increased ICP is one of the poor prognostic factors for patient survival\(^{18,32,34}\). Compartment model of CSF flow predicts that simple diffusion cannot achieve even distribution of injected drugs in case of disturbed CSF flow, as the diffusion distance between the ventricle and lumbar subarachnoid space is too long to be reached without physiologic CSF flow\(^{20}\). As a consequence, increased gradient and transit time of injected drugs in the lateral ventricle facilitate penetration into brain parenchyma and causes encephalopathy\(^{31,32}\). Siegel et al.\(^{30}\) report that the incidence of delayed leukoencephalopathy in LMC patients treated with intraventricular chemotherapy significantly correlates with increased ICP.

Perfusion of chemotherapeutic drug from one lateral ventricle to another or lumbar space was tried by Rubin et al.\(^{52}\) for the purpose of treating glioma or meningeal leukemia while reducing systemic absorption. Later, Nakagawa et al.\(^{49}\) attempt “ventriculolumbar perfusion” (VLP) chemotherapy to increase drug delivery to the lumbar subarachnoid space. MTX is injected into the ventricle as a bolus while artificial CSF is perfused from the ventricle to lumbar drainage for 3 days on VLP in LMC patients from solid cancers (Fig. 1). While 3 out of 6 bed-ridden patients unexpectedly achieved ambulation after VLP, all 13 patients transiently suffered from severe nausea, vomiting, headache, fever, and confusion. Nakagawa et al.\(^{49}\) propose further investigation to establish appropriate drug doses and perfusate volume, while they stop VLP due to the unacceptable toxicities as compared to standard intrathecal chemotherapy. A phase I study of VLP by Gwak et al.\(^{36}\) suggests both perfusion rate and daily MTX dose as variables for MTD. They introduce a continuous infusion of MTX and artificial CSF mixture to human clinical trial for the first time with proven effective CSF concentration at a lower dose of MTX than bolus injection in the non-human pri-mate model\(^{31}\). Perfusion rate of 20 mL/h and daily MTX dose of 24 mg is well-tolerated in patients. The surprising control rate of increased ICP (75%) has prompted phase II trial of VLP. Subsequent phase II trial shows significantly high control rate of increased ICP (71% in 45 patients, median time-to-ICP control of

**Fig. 1. Illustrative photo of ventriculolumbar perfusion chemotherapy. CSF : cerebrospinal fluid, MTX : methotrexate.**
104 days) and prolonged OS of 6.0 months with 19% of improved ambulatory function including 4 bed ridden patients who became ambulatory. The study shows that the OS of NSCLC patients with LMC is double that of conventional NSCLC patients with LMC (3.0 months vs. 6.0 months, p<0.001). VLP thus shows following advantages 1) VLP can be applied to patients with increased ICP, for whom conventional intra-CSF therapy cannot be applied or is ineffective, 2) both symptom improvement rate and OS is significantly improved in these patients who have bad prognostic clinical factors. Further investigation to reduce the constitutive side effects of VLP (nausea, vomiting and confusion) by reducing perfusion rate is on-going.

CONCLUSION

We also need a pharmacodynamic marker for intra-CSF chemotherapy to monitor the treatment response and to set a therapeutic end point. However, current CSF cytology examination is neither valid for complete/partial remission nor appropriate for quantitative measurement of cancer cell burden. Quantitative measurement of cancer metabolites or exosomes is on-going, but a correlation with clinical status is not yet proven. Subpial deposit of cancer cells is more commonly found than free floating cells in the CSF flow, hence simple measurement of CSF values does not fully represent the cancer cell burden of LMC. Thus, elaborate analyses of these variables should combine clinical information such as the post-treatment time of CSF sample and the patient's clinical status.

FUTURE DIRECTIONS INCLUDING BIOLOGICAL/PHARMACODYNAMIC MARKERS

As CSF cytology shows frequent false negative results, investigators have sought more predictive diagnostic values for CSF profiles such as elevated protein levels, low glucose, and increased lactate dehydrogenase/β-glucosidase/β-2 microglobulin etc. or a combination of these values. However, they are consistent with, but not diagnostic of LMC, and investigators are unable to provide cut-off values of the diagnostic variables agreeable to clinicians. Tumor specific antigens such as CA 19-9, Cyfra 21-1 or CEA have higher sensitivity and specificity than CSF cytology or other markers. But, they do not appear in all patients that have these primary cancers. Recent efforts to find a small amount of onco-protein, onco-DNA or onco-microRNA in CSF utilizing advances in molecular biological techniques show promising results, but the pilot studies need to be validated in a large number of patients including a control group.

We also need a pharmacodynamic marker for intra-CSF chemotherapy to monitor the treatment response and to set a therapeutic end point. However, current CSF cytology examination is neither valid for complete/partial remission nor appropriate for quantitative measurement of cancer cell burden. Quantitative measurement of cancer metabolites or exosomes is on-going, but a correlation with clinical status is not yet proven. Subpial deposit of cancer cells is more commonly found than free floating cells in the CSF flow, hence simple measurement of CSF values does not fully represent the cancer cell burden of LMC. Thus, elaborate analyses of these variables should combine clinical information such as the post-treatment time of CSF sample and the patient's clinical status.

CONCLUSION

Prognosis of patients with LMC from solid tumors is still dismal without a cure despite intra-CSF chemotherapy. However, major problems of intra-CSF chemotherapy can be solved by developing more available drugs to overcome drug-resistance and advancement of drug delivering technique such as VLP. Elaborate search for biomarker/pharmacodynamic marker combined with clinical findings would greatly facilitate the introduction of new drugs and technologies to clinical trials for LMC.

References

1. Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG: Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol 45: 259-264, 2000
2. Baramski A, Kuhnemann J, Schlegel U, Schmiesel W, Hahn S, Schwers R: MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neurocol 109: 239-244, 2012
3. Bernardi RJ, Bornsaga L, Fox E, Balis FM, Egorin MJ, Lagattuta TE et al.: Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol 62: 355-361, 2008
4. Blaney SM, Balis FM, Berg S, Arndt CA, Heideman R, Geyer JR et al.: Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 23: 1555-1563, 2005
5. Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowitz M et al.: Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol 23: 525-531, 2005
6. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG: Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53: 725-727, 1993
7. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR et al.: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21: 143-147, 2003
8. Blaney SM, Kocak M, Gajjar A, Chintagumpala M, Merchant T, Kieran M et al.: Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol 109: 565-571, 2012
9. Balis SM, Poplack DG: New cytotoxic drugs for intrathecal administration. J Neurooncol 38: 219-223, 1998
10. Blasberg RG, Patlak CS, Shapiro WR: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Res 61: 633-641, 1977
11. Bokstein F, Lossos A, Lossos IS, Siegal T: Central nervous system relapse of systemic non-Hodgkin’s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 43: 587-593, 2002
12. Bokstein F, Lossos A, Siegal T: Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intracerebrospinal fluid chemotherapy. Cancer 82: 1756-1763, 1998
13. Boogerd W, van den Bent MJ, Koehler PJ, Heimans J, van der Sande JL, Aaronson NK et al.: The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40: 2726-2733, 2004
14. Bruno J, Gonzalez L, Miró J, Velasco R, Gil M, Tortosa A et al.: Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115: 381-389, 2009
15. Chamberlain MC: Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol 37: 271-284, 1998
16. Chamberlain MC: Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 38: 135-140, 1998
17. Chamberlain MC, Kornamik P: Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55: 506-512, 1998
18. Chamberlain MC, Kornamik PA: Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46: 6.
19. Chamberlain MC, Kormanik PA, Barba D: Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87: 694-699, 1997
20. Clarke JL, Pau W, Wu N, Miller VA, Lassman AB: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99: 283-286, 2010
21. de Azevedo CR, Cruz MR, Chamen JI, Perez SV, Peterlevitz MA, de Azevedo Pereira AE, et al.: Meningeal carcinomatosis in breast cancer: a phase I study of ganciclovir. J Neurooncol 104: 565-572, 2011
22. Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, et al.: Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res 8: 2437-2442, 2002
23. Fizazi K, Asselin B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, et al.: Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77: 1315-1323, 1996
24. Fleischhack G, Jarzab U, Bode U: Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 44: 1-31, 2005
25. Freidich RJ, Krol G, deAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38: 51-57, 1995
26. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al.: Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 21: 2183-2187, 2010
27. Glantz MJ, Jaedke KA, Chamberlain MC, Phuphanich S, Recht L, Sweeney LJ, et al.: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5: 3394-3402, 1999
28. Glass JP, Melamed M, Chernik NL, Posner JB: Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29: 1369-1375, 1979
29. Gleissner B, Chamberlain MC: Neoplastic meningitis. Lancet Neurol 5: 443-452, 2006
30. Grossman SA, Krabak MJ: Leptomeningeal carcinomatosis. Cancer Treat Rev 25: 103-119, 1999
31. Grossman SA, Reinhard CS, Louts HI: The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurosurg 7: 319-328, 1989
32. Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Ann J Med 73: 641-647, 1982
33. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, et al.: Phase I trial of intraventricular sparganum buxulain in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res 12: 1540-1546, 2006
34. Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, et al.: Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 8: 599-605, 2013.
35. Gwak HS, Joo J, Shin SH, Yoo H, Han JY, Kim HT, et al.: Ventricularolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study. Oncologist 19: 1044-1045, 2014
36. Gwak HS, Lim HS, Shin SH, Yoo H, Han JY, Kim HT, et al.: Ventricularolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data. Am J Clin Oncol 36: 491-499, 2013
37. Herrlinger U, Firschler H, Küker W, Meyermann R, Bamberg M, Dichgans J, et al.: Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 223: 167-178, 2004
38. Hitchins RN, Bell DR, Woods RL, Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5: 1655-1662, 1987
39. Hofer S, Mengele K, Stemmler HJ, Schmitt M, Pestalozzi B: Intrathecal trastuzumab: dose matters. Acta Oncol 51: 955-956, 2012
40. Kayataya T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, et al.: Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4: 1415-1419, 2009
41. Kim DY, Lee KW, Yun T, Park SR, Jung YJ, Kim DW, et al.: Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumour: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33: 608-612, 2003
42. Lautman LR, Forthoeldt KF: Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2: 235, 2001
43. Levin VA, Byrd D, Campbell J, Giannini DD, Borich JK, Darvish RL: Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricular [3-(4-amino-2-methyl-5-pyrimidinyl)-ethyl]1-(2-chloroethyl)-1-nitro sources and other nitrosoureas in beagles. Cancer Res 45: 3803-3809, 1985
44. Levin VA, Chamberlain M, Silver P, Rodriguez L, Prados M: Phase II study of intraventricular and intrathcal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 23: 301-307, 1989
45. Liu S, Sun J, Lan Q: Glioblastoma microvesicles promote endothelial cell proliferation through Akt/beta-catenin pathway. Int J Clin Exp Pathol 7: 4857-4866, 2014
46. Masuda T, Hattori N, Harnada A, Iwamoto H, Oshiumo S, Kanehara M, et al.: Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 67: 1465-1469, 2011
47. Mittl RR, Jr, Yousem DM: Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. AJNR Am J Neuroradiol 15: 633-638, 1994
48. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al.: Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7: 382-385, 2012
49. Nakagawa H, Fujita T, Kubo S, Izumo S, Nakajima Y, Tsuromoto K, et al.: Ventricularolumbar perfusion chemotherapy with methotrexate and cytosome arabinoside for meningeal carcinomatosis: a pilot study in 13 patients. Surg Neurol 45: 256-264, 1996
50. Ongerhoer de Visser BW, Somers R, Nooyen WH, van Heerde P, Hart AA, McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33: 1565-1572, 1983
51. Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, et al.: Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 76: 387-392, 2012
52. Rubin RC, Ommaya AK, Henderson ES, Bering EA, Rall DP: Cerebrospinal fluid perfusion for central nervous system neoplasms. Neurology 16: 680-692, 1966
53. Sato Y, Ohta Y, Kaji M, Oizumi K, Kaji M: Carbohydrate antigen 19-9 and treatment of meningeal carcinomatosis in ten patients with breast cancer. Eur Neurol 25: 403-411, 1986
54. Shapiro WR, Young DF, Meltha BM: Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N
56. Siegal T, Lossos A, Pfeffer MR: Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. *Neurology* 44: 1463-1469, 1994

57. Straathof CS, de Bruin HG, Dippel DW, Vecht CJ: The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. *J Neurosurg* 246: 810-814, 1999

58. Swinkels DW, de Kok JB, Hanselaar A, Lamers K, Boerman RH: Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. *Clin Chem* 46: 132-133, 2000

59. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY: Leptomeningeal metastases from solid malignancy: a review. *J Neurooncol* 75: 85-99, 2005

60. Tepluk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, et al.: MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. *Neuro Oncol* 14: 689-700, 2012

61. Tetef ML, Margolin KA, Doroshow H, Aleman S, Leong LA, Morgan RJ Jr, et al.: Pharmacokinetiks and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. *Cancer Chemother Pharmacol* 46: 19-26, 2000

62. Tran HC, Gardner S, Weiner HL, Liebes LF, Finlay JL: Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. *J Oncol Pharm Pract* 20: 229-232, 2014

63. Twijnstra A, van Zanten AP, Hart AA, Onkerboer de Visser BW: Serial lumbar and ventricul cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and hematological tumours. *J Neurosurg Psychiatry* 50: 313-320, 1987

64. Twijnstra A, van Zanten AP, Nooyen WJ, Onkerboer de Visser BW: Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer. *J Neurosurg Psychiatry* 49: 1246-1250, 1986

65. Waki F, Ando M, Takashima A, Yonemori K, Nokihara H, Miyake M, et al.: Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. *J Neurooncol* 93: 205-212, 2009

66. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. *Cancer* 49: 759-772, 1982

67. Yi HG, Kim HJ, Kim YI, Han SW, Oh DY, Lee SH, et al.: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. *Lung Cancer* 65: 80-84, 2009

68. Yousem DM, Patrone PM, Grossman RI: Leptomeningeal metastases: MR evaluation. *J Comput Assist Tomogr* 14: 255-261, 1990

69. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysiakos D, de Azambuja E, et al.: Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. *Breast Cancer Res Treat* 139: 13-22, 2013